

**Department of Psychiatry and Neurosciences**

USF Health · College of Medicine

Office of the Chair - Week of August 8-12, 2011

**Website: <http://www.hsc.usf.edu/PSYCH/>**

**Newsletter**

Meetings

Thursday 08/11/11 8:00 a.m. Call Center Meeting

Resident Lectures:

- 8:00 a.m. CHILD - "Soft Neurological Signs" Dr. Tanya Murphy
- 9:00 a.m. CHILD - "Dysmorphic Features" Dr. Tanya Murphy
- 10:00 a.m. PGY-2, 3 and 4 - "TMS" Dr. Gabriel de Erausquin (at STC)
- CHILD - "Autism" Dr. Sandra Stock
- 11:00 a.m. PGY-2, 3 and 4 - "TMS Display" Dr. Francisco Fernandez (at STC)
- 12:00 noon PGY-2, 3 and 4 - "CV Review" Dr. Francisco Fernandez (at STC)
- 12:00 noon NO GRAND ROUNDS
- 1:00 p.m. Geriatric Education Committee Meeting

Friday 08/12/11

Medical Student Lectures

- 8:00 a.m. "Psychiatric Emergencies" Dr. Sandra Stock
- 9:00 a.m. "Psychopharmacology" Dr. Glenn Catalano
- 1:00 p.m. "Neurological Emergencies" Dr. Rossitza Chichkova
- 3:00 p.m. "Neurovascular Disease - Ischemic Stroke" Dr. David Decker
- 4:00 p.m. "Neurovascular Disease - ICH" Dr. David Decker

**In The Know!**

*Happy Birthday wishes to Claire Desir/August 11<sup>th</sup>.*

# Research Happenings!

Current Open Studies – Call [813-974-2832](tel:813-974-2832) or [813-974-1404](tel:813-974-1404) for more information on any study or to refer a patient.

## Bipolar I Disorder with Depressive Symptoms

The Department is participating in a nationwide clinical research study evaluating the efficacy and safety of an investigational medication used as adjunctive therapy in patients with major depression associated with Bipolar I Disorder. This is a 15-week outpatient study. Patients must be 18-65 years of age and currently experiencing depressive symptoms. Patients must be on Lithium, Depakote, Lamictal, Abilify, Zyprexa, Risperdal, CONSTA, or Geodon. Assistance in obtaining Lithium and Depakote is available during the course of the study. Principal Investigator – Carlos Santana, M.D.

## Schizophrenia PRIDE Study – Jail Recidivism

A 15-month open label study comparing oral antipsychotic treatment to paliperidone palmitate injections in delaying arrest recidivism in adults with Schizophrenia. Subjects must have been incarcerated at least twice in the last 24 months with the last release from jail occurring within 90 days prior to screening. Subjects receive antipsychotic medications at no charge. Principal Investigator – Jean Fils, M.D.

## NEW AUTISM STUDY

We are happy to announce USF Psychiatry's participation in a Phase 4, Safety and Efficacy study of Aripiprazole in the long-term maintenance treatment of children and adolescents 6-17 years of age with irritability associated with Autistic Disorder. The study is divided into three phases – a 7-42 day screening period, a 13-26 week single-blind phase, and a 16-week double-blind, placebo-controlled phase. Kids ages 6-17 with autism are eligible to screen for this study. Call 813-974-2832 for more information. Principal Investigator – Mike Bengtson, MD.

## Now Open and Enrolling – ADHD Aggression Study

Kids between the ages of 6-12 years old and in generally good health with a diagnosis of ADHD are eligible to participate in a 10-week investigational medication trial. Children must be receiving stimulant medication treatment for ADHD symptoms for 1 month prior to study enrollment and be experiencing aggressive behaviors. This study is a 10 week investigational medication trial that will test the effectiveness and safety of molindone hydrochloride extended release as an add-on treatment for aggressive behaviors in children with ADHD. Principal Investigator – Mike Bengtson, MD.

### Coming Soon - Bipolar I in Teens

This study is a 3- week investigational medication trial that will test the effectiveness and safety of asenapine compared to placebo in teens ages 12-17 with Bipolar I disorder who are currently experiencing a manic or mixed episode. A 26-week extension study is available. Study medication, study visits, and required laboratory work provided at no cost. Volunteers must be between the ages of 12-17 years old and in generally good health with a diagnosis of Bipolar I disorder and currently experiencing manic or mixed symptoms. Principal Investigator - Mike Bengtson, MD.

Study-related care will include a comprehensive diagnostic exam, physical exam, laboratory testing, ECG and frequent doctor visits, as well as investigational medication, all at no charge. This is a placebo controlled trial and all participants who complete the study will have the option to enroll in an open label 6 month extension study. Enrolled patients will be compensated for time and travel.

<http://health.usf.edu/medicine/psychiatry/research/index.htm>